A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Inclusion Criteria: * Male and female subjects 18 to 65 years of age. * Signed informed consent. * Diagnosis of CHB and candidates for therapy * Normal renal function * Women of childbearing potential must have a serum negative pregnancy test at screening. Women of childbearing potential and males whose sexual partners are of childbearing potential must agree to use dual methods of contraception. Exclusion Criteria: * Liver disease other than CHB * Documented co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), or HIV * Previous therapy with interferon alpha. * Any other antiviral therapy for chronic hepatitis B within the previous 3 months prior to Screening Visit. * Immunosuppressive treatment (e.g. chemotherapy, high-dose of steroids) within 6 months of Screening Visit. * Evidence of cirrhosis * Child-Turcotte-Pugh (CTP) score ≥ 7, either currently or at any occasion in the past * Clinically significant acute or chronic illnesses, such as autoimmune diseases, collagen vascular disease, immune deficiencies, active or uncontrolled infections, etc. as determined by the investigator and documented in medical history. * Malignancy other than curatively treated, superficial skin cancer or carcinoma in situ of the cervix. * Participation in any experimental protocol or therapy within 28 days prior to the Screening Visit. * Current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of study results.